NCT00624702 - Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Asthma

Interventions

DRUG

Indacaterol maleate

Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval

DRUG

Indacaterol maleate

Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval

DRUG

Indacaterol maleate

Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval

DRUG

Placebo

Trial Locations (2)

Novartis Investigator Site, Ottawa

Novartis Investigator Site, Montreal